Invention Grant
- Patent Title: 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors
-
Application No.: US15874987Application Date: 2018-01-19
-
Publication No.: US10329308B2Publication Date: 2019-06-25
- Inventor: Michael Aaron Brodney , Christopher Ryan Butler , Laura Ann McAllister , Christopher John Helal , Steven Victor O'Neil , Patrick Robert Verhoest
- Applicant: PFIZER INC.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent Feng Shao
- Main IPC: C07D513/10
- IPC: C07D513/10 ; C07D221/20 ; C07D295/185 ; C07D401/08 ; C07D401/12 ; C07D491/10

Abstract:
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
Public/Granted literature
- US20180208607A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS Public/Granted day:2018-07-26
Information query